Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT-I10A plus docetaxel vs placebo plus docetaxel in squamous NSCLC
CTR20192593Phase 3Terminated
- Sponsor
- Shenzhou Cell Engineering Co., Ltd.
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of finotonlimab in Pulmonary squamous cell carcinoma, sponsored by Shenzhou Cell Engineering Co., Ltd.. Started Jan 2020; status: terminated.
02
Drugs
finotonlimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20192593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192593.